JP5178982B2 - 経口投薬形態における、毒性コアの非毒性領域中へのカプセル化 - Google Patents
経口投薬形態における、毒性コアの非毒性領域中へのカプセル化 Download PDFInfo
- Publication number
- JP5178982B2 JP5178982B2 JP2001583741A JP2001583741A JP5178982B2 JP 5178982 B2 JP5178982 B2 JP 5178982B2 JP 2001583741 A JP2001583741 A JP 2001583741A JP 2001583741 A JP2001583741 A JP 2001583741A JP 5178982 B2 JP5178982 B2 JP 5178982B2
- Authority
- JP
- Japan
- Prior art keywords
- dosage form
- region
- bulk material
- active agent
- pharmaceutically active
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 231100000331 toxic Toxicity 0.000 title claims abstract description 63
- 230000002588 toxic effect Effects 0.000 title claims abstract description 63
- 231100000252 nontoxic Toxicity 0.000 title claims abstract description 28
- 230000003000 nontoxic effect Effects 0.000 title claims abstract description 28
- 239000006186 oral dosage form Substances 0.000 title abstract description 28
- 238000005538 encapsulation Methods 0.000 title description 3
- 239000003814 drug Substances 0.000 claims abstract description 115
- 229940079593 drug Drugs 0.000 claims abstract description 107
- 239000002552 dosage form Substances 0.000 claims abstract description 75
- 239000000843 powder Substances 0.000 claims abstract description 70
- 239000007788 liquid Substances 0.000 claims abstract description 62
- 239000007787 solid Substances 0.000 claims abstract description 41
- 239000002245 particle Substances 0.000 claims abstract description 37
- 238000004519 manufacturing process Methods 0.000 claims abstract description 34
- 230000003389 potentiating effect Effects 0.000 claims abstract description 26
- 238000010146 3D printing Methods 0.000 claims abstract description 9
- 238000000034 method Methods 0.000 claims description 67
- 239000011230 binding agent Substances 0.000 claims description 65
- 239000013543 active substance Substances 0.000 claims description 44
- 239000013590 bulk material Substances 0.000 claims description 43
- 230000007704 transition Effects 0.000 claims description 40
- 239000012530 fluid Substances 0.000 claims description 21
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 17
- 239000002775 capsule Substances 0.000 claims description 15
- 230000008569 process Effects 0.000 claims description 15
- 239000000126 substance Substances 0.000 claims description 15
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 14
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 13
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 13
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical group OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 13
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 10
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 10
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 9
- 238000007639 printing Methods 0.000 claims description 9
- VHXNKPBCCMUMSW-FQEVSTJZSA-N rubitecan Chemical compound C1=CC([N+]([O-])=O)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VHXNKPBCCMUMSW-FQEVSTJZSA-N 0.000 claims description 9
- 229950009213 rubitecan Drugs 0.000 claims description 9
- 239000002246 antineoplastic agent Substances 0.000 claims description 8
- 229940088597 hormone Drugs 0.000 claims description 8
- 239000005556 hormone Substances 0.000 claims description 8
- 231100000419 toxicity Toxicity 0.000 claims description 8
- 230000001988 toxicity Effects 0.000 claims description 8
- 239000002111 antiemetic agent Substances 0.000 claims description 7
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical group C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 claims description 7
- 229940124531 pharmaceutical excipient Drugs 0.000 claims description 7
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 6
- 229920002125 Sokalan® Polymers 0.000 claims description 6
- 230000001070 adhesive effect Effects 0.000 claims description 6
- 239000004014 plasticizer Substances 0.000 claims description 6
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 claims description 5
- 108010010803 Gelatin Proteins 0.000 claims description 5
- AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical compound IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 claims description 5
- 239000000654 additive Substances 0.000 claims description 5
- 239000000853 adhesive Substances 0.000 claims description 5
- 229940127093 camptothecin Drugs 0.000 claims description 5
- 150000001875 compounds Chemical class 0.000 claims description 5
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 claims description 5
- 239000008273 gelatin Substances 0.000 claims description 5
- 229920000159 gelatin Polymers 0.000 claims description 5
- 235000019322 gelatine Nutrition 0.000 claims description 5
- 235000011852 gelatine desserts Nutrition 0.000 claims description 5
- 239000003349 gelling agent Substances 0.000 claims description 5
- 229920001477 hydrophilic polymer Polymers 0.000 claims description 5
- 239000002202 Polyethylene glycol Substances 0.000 claims description 4
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 4
- 230000003111 delayed effect Effects 0.000 claims description 4
- 229920000609 methyl cellulose Polymers 0.000 claims description 4
- 239000001923 methylcellulose Substances 0.000 claims description 4
- 235000010981 methylcellulose Nutrition 0.000 claims description 4
- 229920001223 polyethylene glycol Polymers 0.000 claims description 4
- 229920005606 polypropylene copolymer Polymers 0.000 claims description 4
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 4
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims description 3
- 229920002261 Corn starch Polymers 0.000 claims description 3
- 229920002148 Gellan gum Polymers 0.000 claims description 3
- 229920000161 Locust bean gum Polymers 0.000 claims description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 3
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 3
- 150000005215 alkyl ethers Chemical class 0.000 claims description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 230000000295 complement effect Effects 0.000 claims description 3
- 239000008120 corn starch Substances 0.000 claims description 3
- 235000010492 gellan gum Nutrition 0.000 claims description 3
- 239000000216 gellan gum Substances 0.000 claims description 3
- 235000010420 locust bean gum Nutrition 0.000 claims description 3
- 239000000711 locust bean gum Substances 0.000 claims description 3
- 230000000873 masking effect Effects 0.000 claims description 3
- -1 polyoxyethylene Polymers 0.000 claims description 3
- 239000000741 silica gel Substances 0.000 claims description 3
- 229910002027 silica gel Inorganic materials 0.000 claims description 3
- 235000010413 sodium alginate Nutrition 0.000 claims description 3
- 239000000661 sodium alginate Substances 0.000 claims description 3
- 229940005550 sodium alginate Drugs 0.000 claims description 3
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 3
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 3
- 150000003431 steroids Chemical class 0.000 claims description 3
- 235000000346 sugar Nutrition 0.000 claims description 3
- 239000000375 suspending agent Substances 0.000 claims description 3
- 239000000230 xanthan gum Substances 0.000 claims description 3
- 235000010493 xanthan gum Nutrition 0.000 claims description 3
- 229920001285 xanthan gum Polymers 0.000 claims description 3
- 229940082509 xanthan gum Drugs 0.000 claims description 3
- 230000009471 action Effects 0.000 claims description 2
- 229940041181 antineoplastic drug Drugs 0.000 claims description 2
- 229940035722 triiodothyronine Drugs 0.000 claims 3
- 230000000996 additive effect Effects 0.000 claims 2
- 230000003444 anaesthetic effect Effects 0.000 claims 1
- 230000007423 decrease Effects 0.000 claims 1
- 239000003193 general anesthetic agent Substances 0.000 claims 1
- 231100000086 high toxicity Toxicity 0.000 claims 1
- 238000000576 coating method Methods 0.000 abstract description 17
- 239000000725 suspension Substances 0.000 abstract description 12
- 238000002955 isolation Methods 0.000 abstract description 7
- 230000007928 solubilization Effects 0.000 abstract description 6
- 238000005063 solubilization Methods 0.000 abstract description 6
- 238000012377 drug delivery Methods 0.000 abstract description 3
- 239000000383 hazardous chemical Substances 0.000 abstract description 2
- 230000000740 bleeding effect Effects 0.000 description 15
- 239000000463 material Substances 0.000 description 14
- 239000011248 coating agent Substances 0.000 description 12
- 230000000694 effects Effects 0.000 description 9
- 230000000875 corresponding effect Effects 0.000 description 7
- 238000010586 diagram Methods 0.000 description 7
- 230000007246 mechanism Effects 0.000 description 7
- 230000008901 benefit Effects 0.000 description 6
- 238000010521 absorption reaction Methods 0.000 description 5
- 239000000499 gel Substances 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 230000033001 locomotion Effects 0.000 description 5
- 239000004094 surface-active agent Substances 0.000 description 5
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 4
- 230000003474 anti-emetic effect Effects 0.000 description 4
- 239000000428 dust Substances 0.000 description 4
- 239000007903 gelatin capsule Substances 0.000 description 4
- 239000000693 micelle Substances 0.000 description 4
- 239000008108 microcrystalline cellulose Substances 0.000 description 4
- 229940016286 microcrystalline cellulose Drugs 0.000 description 4
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 239000007900 aqueous suspension Substances 0.000 description 3
- 230000004888 barrier function Effects 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 238000009792 diffusion process Methods 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 238000004806 packaging method and process Methods 0.000 description 3
- 239000011236 particulate material Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 238000007906 compression Methods 0.000 description 2
- 230000006835 compression Effects 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000010100 freeform fabrication Methods 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 239000010437 gem Substances 0.000 description 2
- 229910001751 gemstone Inorganic materials 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 201000002528 pancreatic cancer Diseases 0.000 description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 description 2
- 230000009919 sequestration Effects 0.000 description 2
- 239000002002 slurry Substances 0.000 description 2
- 239000007909 solid dosage form Substances 0.000 description 2
- 231100000925 very toxic Toxicity 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 238000011394 anticancer treatment Methods 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- CEZCCHQBSQPRMU-UHFFFAOYSA-L chembl174821 Chemical compound [Na+].[Na+].COC1=CC(S([O-])(=O)=O)=C(C)C=C1N=NC1=C(O)C=CC2=CC(S([O-])(=O)=O)=CC=C12 CEZCCHQBSQPRMU-UHFFFAOYSA-L 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000005056 compaction Methods 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000007598 dipping method Methods 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000007888 film coating Substances 0.000 description 1
- 238000009501 film coating Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 150000008282 halocarbons Chemical class 0.000 description 1
- 239000007887 hard shell capsule Substances 0.000 description 1
- 239000013056 hazardous product Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 229960001375 lactose Drugs 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000004081 narcotic agent Substances 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 150000003014 phosphoric acid esters Chemical class 0.000 description 1
- 239000002861 polymer material Substances 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 238000012805 post-processing Methods 0.000 description 1
- 238000009702 powder compression Methods 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 238000000110 selective laser sintering Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000005495 thyroid hormone Substances 0.000 description 1
- 229940036555 thyroid hormone Drugs 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2893—Tablet coating processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B33—ADDITIVE MANUFACTURING TECHNOLOGY
- B33Y—ADDITIVE MANUFACTURING, i.e. MANUFACTURING OF THREE-DIMENSIONAL [3-D] OBJECTS BY ADDITIVE DEPOSITION, ADDITIVE AGGLOMERATION OR ADDITIVE LAYERING, e.g. BY 3-D PRINTING, STEREOLITHOGRAPHY OR SELECTIVE LASER SINTERING
- B33Y10/00—Processes of additive manufacturing
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B33—ADDITIVE MANUFACTURING TECHNOLOGY
- B33Y—ADDITIVE MANUFACTURING, i.e. MANUFACTURING OF THREE-DIMENSIONAL [3-D] OBJECTS BY ADDITIVE DEPOSITION, ADDITIVE AGGLOMERATION OR ADDITIVE LAYERING, e.g. BY 3-D PRINTING, STEREOLITHOGRAPHY OR SELECTIVE LASER SINTERING
- B33Y70/00—Materials specially adapted for additive manufacturing
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B33—ADDITIVE MANUFACTURING TECHNOLOGY
- B33Y—ADDITIVE MANUFACTURING, i.e. MANUFACTURING OF THREE-DIMENSIONAL [3-D] OBJECTS BY ADDITIVE DEPOSITION, ADDITIVE AGGLOMERATION OR ADDITIVE LAYERING, e.g. BY 3-D PRINTING, STEREOLITHOGRAPHY OR SELECTIVE LASER SINTERING
- B33Y80/00—Products made by additive manufacturing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Materials Engineering (AREA)
- Manufacturing & Machinery (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US20589600P | 2000-05-18 | 2000-05-18 | |
| US60/205,896 | 2000-05-18 | ||
| PCT/US2001/040763 WO2001087272A2 (en) | 2000-05-18 | 2001-05-18 | Encapsulating a toxic core within a non-toxic region in an oral dosage form |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012012834A Division JP2012082224A (ja) | 2000-05-18 | 2012-01-25 | 経口投薬形態における、毒性コアの非毒性領域中へのカプセル化 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2003533470A JP2003533470A (ja) | 2003-11-11 |
| JP2003533470A5 JP2003533470A5 (enExample) | 2008-07-17 |
| JP5178982B2 true JP5178982B2 (ja) | 2013-04-10 |
Family
ID=22764098
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001583741A Expired - Fee Related JP5178982B2 (ja) | 2000-05-18 | 2001-05-18 | 経口投薬形態における、毒性コアの非毒性領域中へのカプセル化 |
| JP2012012834A Withdrawn JP2012082224A (ja) | 2000-05-18 | 2012-01-25 | 経口投薬形態における、毒性コアの非毒性領域中へのカプセル化 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012012834A Withdrawn JP2012082224A (ja) | 2000-05-18 | 2012-01-25 | 経口投薬形態における、毒性コアの非毒性領域中へのカプセル化 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US7276252B2 (enExample) |
| EP (1) | EP1286663B1 (enExample) |
| JP (2) | JP5178982B2 (enExample) |
| AT (1) | ATE315930T1 (enExample) |
| AU (1) | AU2001263506A1 (enExample) |
| CA (1) | CA2408956C (enExample) |
| DE (1) | DE60116758T2 (enExample) |
| ES (1) | ES2257412T3 (enExample) |
| WO (1) | WO2001087272A2 (enExample) |
Families Citing this family (90)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030118645A1 (en) * | 1998-04-29 | 2003-06-26 | Pather S. Indiran | Pharmaceutical compositions for rectal and vaginal administration |
| US6544555B2 (en) * | 2000-02-24 | 2003-04-08 | Advancis Pharmaceutical Corp. | Antibiotic product, use and formulation thereof |
| US6565882B2 (en) * | 2000-02-24 | 2003-05-20 | Advancis Pharmaceutical Corp | Antibiotic composition with inhibitor |
| US6541014B2 (en) * | 2000-10-13 | 2003-04-01 | Advancis Pharmaceutical Corp. | Antiviral product, use and formulation thereof |
| US20020068078A1 (en) * | 2000-10-13 | 2002-06-06 | Rudnic Edward M. | Antifungal product, use and formulation thereof |
| US6518330B2 (en) * | 2001-02-13 | 2003-02-11 | Board Of Trustees Of University Of Illinois | Multifunctional autonomically healing composite material |
| WO2003037244A2 (en) * | 2001-10-29 | 2003-05-08 | Therics, Inc. | System for manufacturing controlled release dosage forms, such as a zero-order release profile dosage form manufactured by three-dimensional printing |
| CA2463481A1 (en) * | 2001-10-29 | 2003-05-22 | Therics, Inc. | Three-dimensional suspension printing of dosage forms |
| WO2003037607A1 (en) * | 2001-10-29 | 2003-05-08 | Therics, Inc. | A system and method for uniaxial compression of an article, such as a three-dimensionally printed dosage form |
| CA2483028C (en) | 2002-05-06 | 2011-04-05 | Massachusetts Institute Of Technology | Diffusion-controlled dosage form and method of fabrication including three dimensional printing |
| CA2533292C (en) | 2003-07-21 | 2013-12-31 | Advancis Pharmaceutical Corporation | Antibiotic product, use and formulation thereof |
| US8425936B2 (en) * | 2003-07-21 | 2013-04-23 | Shionogi Inc. | Antibiotic product, use and formulation thereof |
| WO2005009365A2 (en) * | 2003-07-21 | 2005-02-03 | Advancis Pharmaceutical Corporation | Antibiotic product, use and formulation thereof |
| WO2005016311A1 (en) * | 2003-08-11 | 2005-02-24 | Advancis Pharmaceutical Corporation | Robust pellet |
| CA2535398C (en) * | 2003-08-12 | 2013-11-12 | Advancis Pharmaceuticals Corporation | Antibiotic product, use and formulation thereof |
| AU2004270170B2 (en) * | 2003-08-29 | 2011-01-27 | Shionogi, Inc. | Antibiotic product, use and formulation thereof |
| US8460710B2 (en) * | 2003-09-15 | 2013-06-11 | Shionogi, Inc. | Antibiotic product, use and formulation thereof |
| US20050087902A1 (en) * | 2003-10-28 | 2005-04-28 | Isaac Farr | Alginate-based materials, methods of application thereof, and systems for using the alginate-based materials |
| JP2007517039A (ja) * | 2003-12-24 | 2007-06-28 | アドバンシス ファーマスーティカル コーポレイション | 変性放出製剤の吸収増強 |
| US7566747B2 (en) * | 2004-05-07 | 2009-07-28 | The Board Of Trustees Of The University Of Illinois | Wax particles for protection of activators, and multifunctional autonomically healing composite materials |
| TWI547431B (zh) * | 2004-06-09 | 2016-09-01 | 史密斯克萊美占公司 | 生產藥物之裝置及方法 |
| US20060002594A1 (en) * | 2004-06-09 | 2006-01-05 | Clarke Allan J | Method for producing a pharmaceutical product |
| JPWO2006004069A1 (ja) * | 2004-07-01 | 2008-04-24 | 日本碍子株式会社 | 微小カプセルおよびその製造方法 |
| US8715727B2 (en) * | 2004-07-02 | 2014-05-06 | Shionogi Inc. | Tablet for pulsed delivery |
| EP1827391B1 (en) * | 2004-11-26 | 2015-09-23 | Aprecia Pharmaceuticals Co. | Three dimensionally printed dosage forms |
| US7829000B2 (en) * | 2005-02-25 | 2010-11-09 | Hewlett-Packard Development Company, L.P. | Core-shell solid freeform fabrication |
| US7612152B2 (en) * | 2005-05-06 | 2009-11-03 | The Board Of Trustees Of The University Of Illinois | Self-healing polymers |
| US7914776B2 (en) * | 2005-10-07 | 2011-03-29 | Adolor Corporation | Solid dispersions of opioid antagonists |
| US8778924B2 (en) * | 2006-12-04 | 2014-07-15 | Shionogi Inc. | Modified release amoxicillin products |
| US8357394B2 (en) | 2005-12-08 | 2013-01-22 | Shionogi Inc. | Compositions and methods for improved efficacy of penicillin-type antibiotics |
| WO2007082153A2 (en) * | 2006-01-05 | 2007-07-19 | The Board Of Trustees Of The University Of Illinois | Self-healing coating system |
| GB0608402D0 (en) * | 2006-04-28 | 2006-06-07 | Diurnal Ltd | Thyroid treatment |
| US8299052B2 (en) | 2006-05-05 | 2012-10-30 | Shionogi Inc. | Pharmaceutical compositions and methods for improved bacterial eradication |
| US7569625B2 (en) * | 2006-06-02 | 2009-08-04 | The Board Of Trustees Of The University Of Illinois | Self-healing elastomer system |
| JP2009544680A (ja) | 2006-07-25 | 2009-12-17 | リポクセン テクノロジーズ リミテッド | ポリサッカライドによるタンパク質のｎ末端誘導体化 |
| US20080107725A1 (en) * | 2006-10-13 | 2008-05-08 | Albano Antonio A | Pharmaceutical Solid Dosage Forms Comprising Amorphous Compounds Micro-Embedded in Ionic Water-Insoluble Polymers |
| US20080299391A1 (en) * | 2007-05-31 | 2008-12-04 | White Scott R | Capsules, methods for making capsules, and self-healing composites including the same |
| WO2009007969A2 (en) * | 2007-07-09 | 2009-01-15 | Colint Ltd. | Portable hydration apparatus |
| US20090181254A1 (en) * | 2008-01-15 | 2009-07-16 | The Board Of Trustees Of The University Of Illinois | Multi-capsule system and its use for encapsulating active agents |
| JP2011074015A (ja) * | 2009-09-30 | 2011-04-14 | Tomita Pharmaceutical Co Ltd | 固形製剤及びその製造方法 |
| DE102010051743B4 (de) | 2010-11-19 | 2022-09-01 | C. Miethke Gmbh & Co. Kg | Programmierbares Hydrocephalusventil |
| MY167883A (en) * | 2011-05-25 | 2018-09-26 | Taiho Pharmaceutical Co Ltd | Dry-coated tablet containing tegafur, gimeracil and oteracil potassium |
| US9381154B2 (en) * | 2011-06-09 | 2016-07-05 | Xerox Corporation | Direct inkjet fabrication of drug delivery devices |
| US8414654B1 (en) * | 2011-11-23 | 2013-04-09 | Amendia, Inc. | Bone implants and method of manufacture |
| CN102551927A (zh) * | 2011-11-29 | 2012-07-11 | 上海大学 | 嵌入式分级释药三维支架及其制备方法 |
| CN105666875B (zh) | 2012-09-05 | 2017-09-12 | 阿普雷奇亚制药公司 | 三维打印系统和设备组件 |
| US8888480B2 (en) | 2012-09-05 | 2014-11-18 | Aprecia Pharmaceuticals Company | Three-dimensional printing system and equipment assembly |
| US20140099351A1 (en) | 2012-10-04 | 2014-04-10 | Axxia Pharmaceuticals, Llc | Process for making controlled release medical implant products |
| WO2014144661A1 (en) | 2013-03-15 | 2014-09-18 | Aprecia Pharmaceuticals Compny | Rapidly dispersible dosage form of topiramate |
| ES2761265T3 (es) * | 2013-03-15 | 2020-05-19 | Aprecia Pharmaceuticals LLC | Forma de dosificación de oxcarbazepina rápidamente dispersable |
| HK1216513A1 (zh) | 2013-03-15 | 2016-11-18 | 阿普雷奇亚制药有限责任公司 | 包含左乙拉西坦的快速分散劑型 |
| US9339489B2 (en) | 2013-03-15 | 2016-05-17 | Aprecia Pharmaceuticals Company | Rapid disperse dosage form containing levetiracetam |
| CN105579161A (zh) | 2013-08-16 | 2016-05-11 | 艾克斯温有限责任公司 | 三维打印的金属铸造模具和其制造方法 |
| EP3057729A4 (en) | 2013-10-17 | 2017-10-18 | The Exone Company | Three-dimensional printed hot isostatic pressing containers and processes for making same |
| WO2015100086A1 (en) | 2013-12-23 | 2015-07-02 | The Exone Company | Methods and systems for three-dimensional printing utilizing multiple binder fluids |
| WO2015100084A1 (en) | 2013-12-23 | 2015-07-02 | The Exone Company | Method of three-dimensional printing using a multi-component build powder |
| US10188739B2 (en) | 2014-02-27 | 2019-01-29 | Xenetic Biosciences, Inc. | Compositions and methods for administering insulin or insulin-like protein to the brain |
| EP3148730A1 (en) | 2014-05-29 | 2017-04-05 | The Exone Company | Process for making nickel-based superalloy articles by three-dimensional printing |
| EP3169499A2 (en) | 2014-07-17 | 2017-05-24 | The Exone Company | Methods and apparatuses for curing three-dimensional printed articles |
| US9854828B2 (en) | 2014-09-29 | 2018-01-02 | William Langeland | Method, system and apparatus for creating 3D-printed edible objects |
| WO2016089618A1 (en) | 2014-12-03 | 2016-06-09 | The Exone Company | Process for making densified carbon articles by three dimensional printing |
| EP4512394A3 (en) | 2015-06-03 | 2025-10-22 | Triastek, Inc. | Dosage forms and use thereof |
| CA2996041A1 (en) | 2015-08-21 | 2017-03-02 | Aprecia Pharmaceuticals LLC | Three-dimensional printing system and equipment assembly |
| AU2016342374B2 (en) | 2015-10-23 | 2022-08-04 | Lyndra Therapeutics, Inc. | Gastric residence systems for sustained release of therapeutic agents and methods of use thereof |
| CN108697649A (zh) | 2015-12-08 | 2018-10-23 | 林德拉有限公司 | 用于胃驻留系统的几何构型 |
| JP6878417B2 (ja) * | 2016-02-17 | 2021-05-26 | トリアステック インコーポレイテッド | 剤形およびそれらの使用 |
| AU2017261372B2 (en) | 2016-05-05 | 2019-02-14 | Triastek, Inc. | Controlled release dosage form |
| CN119925721A (zh) | 2016-05-27 | 2025-05-06 | 林德拉治疗公司 | 用于胃驻留系统的材料结构 |
| US10765658B2 (en) | 2016-06-22 | 2020-09-08 | Mastix LLC | Oral compositions delivering therapeutically effective amounts of cannabinoids |
| GB201612853D0 (en) | 2016-07-25 | 2016-09-07 | Univ Central Lancashire | Solid dosage form production |
| CN118766834A (zh) | 2016-09-30 | 2024-10-15 | 林德拉治疗公司 | 用于金刚烷类药物缓释的胃驻留系统 |
| GB201620066D0 (en) * | 2016-11-28 | 2017-01-11 | Ucl Business Plc | Solid Pharmaceutical dosage formulations and processes |
| CN110290781A (zh) | 2017-01-26 | 2019-09-27 | 南京三迭纪医药科技有限公司 | 胃肠特定部位控制释放的剂型 |
| WO2018156141A1 (en) | 2017-02-24 | 2018-08-30 | Hewlett-Packard Development Company, L.P. | Three-dimensional (3d) printing a pharmaceutical tablet |
| GR1009361B (el) | 2017-05-11 | 2018-09-17 | Κωνσταντινος Ηλια Θεοδοσοπουλος | Συστημα παραγωγης μεσω τρισδιαστατης εκτυπωσης, δισκιων, κοκκιων και καψουλων |
| EP3635045A1 (en) | 2017-05-26 | 2020-04-15 | Infinite Material Solutions, LLC | Water soluble polymer compositions |
| WO2018227147A1 (en) | 2017-06-09 | 2018-12-13 | Lyndra, Inc. | Gastric residence systems with release rate-modulating films |
| US10350822B1 (en) | 2018-01-09 | 2019-07-16 | Triastek Inc. | Dosage forms with desired release profiles and methods of designing and making thereof |
| CN111698983B (zh) | 2018-01-09 | 2022-10-18 | 南京三迭纪医药科技有限公司 | 一种包含固定剂量adhd非兴奋剂和adhd兴奋剂的复方口服药物剂型 |
| DE102018107585B3 (de) * | 2018-03-29 | 2019-03-28 | Universität Rostock | Vorrichtung zur Herstellung von 3D-gedruckten Wirkstofffreisetzungssystemen mit Wirkstoffdepots, sowie Verfahren zur Herstellung von 3D-gedruckten Wirkstofffreisetzungssystemen |
| IT201800004265A1 (it) | 2018-04-06 | 2019-10-06 | Apparato e metodo per la produzione automatizzata di forme di dosaggio personalizzabili. | |
| ES2930199T3 (es) | 2018-10-15 | 2022-12-07 | Aprecia Pharmaceuticals LLC | Método y sistema para formar una forma farmacéutica dentro de un envase |
| EP3908244B1 (de) * | 2019-01-07 | 2024-02-07 | LuxCan Innovation S.A. | Vorrichtung und verfahren für die tablettierung einer pulverförmigen, flüssigen, pastösen, verkapselten oder granularen wirkstoffzusammensetzung |
| US11724486B2 (en) | 2019-07-09 | 2023-08-15 | Kyndryl, Inc. | Printing customized medication based on current user data and medical records of the user |
| GB201913972D0 (en) | 2019-09-27 | 2019-11-13 | Univ Ulster | Pharmaceutical Delivery Device and method of manufacture |
| US12371581B2 (en) | 2020-03-25 | 2025-07-29 | Infinite Material Solutions, Llc | High performance water soluble polymer compositions |
| JP2023533478A (ja) | 2020-06-26 | 2023-08-03 | アプレシア・ファーマスーティカルズ・エルエルシー | 内部空洞を有する迅速口内分散可能な錠剤 |
| KR20230098628A (ko) | 2020-10-30 | 2023-07-04 | 트리아스텍 인코포레이티드 | 위장관 약학적 제형 |
| US12251208B2 (en) | 2020-11-30 | 2025-03-18 | International Business Machines Corporation | Time controlled medication |
| GB2608846A (en) * | 2021-07-14 | 2023-01-18 | Quay Pharmaceuticals Ltd | Method and apparatus for additive manufacturing |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2801203A (en) * | 1951-03-22 | 1957-07-30 | Byk Gulden Lomberg Chem Fab | X-ray method of digestive enzyme diagnosis using protected core of contrast agent |
| US4943579A (en) * | 1987-10-06 | 1990-07-24 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Water soluble prodrugs of camptothecin |
| US5082669A (en) | 1989-07-20 | 1992-01-21 | Dainippon Pharmaceutical Co., Ltd. | Rapid-releasing oral particle pharmaceutical preparation with unpleasant taste masked |
| US5215989A (en) | 1989-12-08 | 1993-06-01 | Merck & Co., Inc. | Nitrogen-containing heterocyclic compounds as class III antiarrhythmic agents |
| US5314696A (en) * | 1991-06-27 | 1994-05-24 | Paulos Manley A | Methods for making and administering a blinded oral dosage form and blinded oral dosage form therefor |
| WO1994009762A1 (en) * | 1992-11-05 | 1994-05-11 | Merck & Co., Inc. | Drug delivery device |
| US6280771B1 (en) * | 1997-02-20 | 2001-08-28 | Therics, Inc. | Dosage forms exhibiting multi-phasic release kinetics and methods of manufacture thereof |
| ZA949929B (en) | 1993-12-23 | 1995-08-23 | Akzo Nobel Nv | Sugar-coated pharmaceutical dosage unit. |
| JPH07223970A (ja) * | 1994-02-10 | 1995-08-22 | Tanabe Seiyaku Co Ltd | 消化管内適所放出製剤 |
| ES2283503T3 (es) * | 1994-04-22 | 2007-11-01 | Astellas Pharma Inc. | Sistema de liberacion de farmaco especifico de colon. |
| US5597829A (en) * | 1994-05-09 | 1997-01-28 | Bionumerik Pharmaceuticals, Inc. | Lactone stable formulation of camptothecin and methods for uses thereof |
| US5783212A (en) * | 1996-02-02 | 1998-07-21 | Temple University--of the Commonwealth System of Higher Education | Controlled release drug delivery system |
| WO1998036739A1 (en) * | 1997-02-20 | 1998-08-27 | Therics, Inc. | Dosage forms exhibiting multiphasic release kinetics and methods of manufacture thereof |
| US6046177A (en) * | 1997-05-05 | 2000-04-04 | Cydex, Inc. | Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations |
| US6294199B1 (en) * | 1999-04-13 | 2001-09-25 | Beecham Pharmaceuticals (Pte) Limited | Method of treating a bacterial infection comprising administering amoxycillin |
-
2001
- 2001-05-18 WO PCT/US2001/040763 patent/WO2001087272A2/en not_active Ceased
- 2001-05-18 DE DE60116758T patent/DE60116758T2/de not_active Expired - Lifetime
- 2001-05-18 ES ES01937808T patent/ES2257412T3/es not_active Expired - Lifetime
- 2001-05-18 US US09/861,480 patent/US7276252B2/en not_active Expired - Lifetime
- 2001-05-18 JP JP2001583741A patent/JP5178982B2/ja not_active Expired - Fee Related
- 2001-05-18 EP EP01937808A patent/EP1286663B1/en not_active Expired - Lifetime
- 2001-05-18 AT AT01937808T patent/ATE315930T1/de not_active IP Right Cessation
- 2001-05-18 CA CA2408956A patent/CA2408956C/en not_active Expired - Fee Related
- 2001-05-18 AU AU2001263506A patent/AU2001263506A1/en not_active Abandoned
-
2005
- 2005-10-07 US US11/246,910 patent/US7875290B2/en not_active Expired - Fee Related
-
2012
- 2012-01-25 JP JP2012012834A patent/JP2012082224A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| EP1286663A2 (en) | 2003-03-05 |
| WO2001087272A3 (en) | 2002-04-18 |
| ES2257412T3 (es) | 2006-08-01 |
| CA2408956A1 (en) | 2001-11-22 |
| EP1286663B1 (en) | 2006-01-18 |
| US20060110443A1 (en) | 2006-05-25 |
| JP2003533470A (ja) | 2003-11-11 |
| CA2408956C (en) | 2011-07-12 |
| ATE315930T1 (de) | 2006-02-15 |
| US7875290B2 (en) | 2011-01-25 |
| US7276252B2 (en) | 2007-10-02 |
| AU2001263506A1 (en) | 2001-11-26 |
| DE60116758D1 (de) | 2006-04-06 |
| DE60116758T2 (de) | 2006-11-02 |
| US20020015728A1 (en) | 2002-02-07 |
| WO2001087272A2 (en) | 2001-11-22 |
| JP2012082224A (ja) | 2012-04-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5178982B2 (ja) | 経口投薬形態における、毒性コアの非毒性領域中へのカプセル化 | |
| US8728521B2 (en) | Physically/molecularly distributed and/or chemically bound medicaments in empty, hard capsule shells | |
| JP2022084945A (ja) | 特定の胃腸部位での制御放出の剤形 | |
| JP2003533470A5 (enExample) | ||
| JP4789806B2 (ja) | パントプラゾール多粒子処方 | |
| JP2023533478A (ja) | 内部空洞を有する迅速口内分散可能な錠剤 | |
| Kaushik et al. | Recent patents and patented technology platforms for pharmaceutical taste masking | |
| JP2005516020A (ja) | ゼロ次持続放出剤形およびその製造方法 | |
| BG65306B1 (bg) | Лекарствена форма с контролирано освобождаване, съдържаща галантамин | |
| WO2007018943A2 (en) | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions | |
| EP2515882A2 (en) | Controlled release pharmaceutical composition | |
| TW202207905A (zh) | 具有內腔的快速口腔分散片劑 | |
| JP2022521317A (ja) | 医薬品の崩壊時間を安定させるための、保管中の薬物粒子コーティング材料の凝集を最小限に抑える | |
| UA82597C2 (uk) | Форма пролонгованого вивільнення гідрохлориду венлафаксину | |
| KR20080026754A (ko) | 생물학적 활성성분을 함유하는 방출 제어형 입자, 및 이의제조방법 | |
| MX2008016565A (es) | Composiciones farmaceuticas que comprenden una combinacion de piperidinoalcanol y descongestivo. | |
| CN115697311A (zh) | 一种琥珀酸多西拉敏和盐酸吡哆醇的改进释放多单位口服剂型及其制备方法 | |
| KR20090029255A (ko) | 생물학적 활성성분을 함유하는 방출 제어형 입자, 및 이의 제조방법 | |
| JP2003137771A (ja) | 難溶性薬物用医薬製剤 | |
| CA2514548A1 (en) | Suspension vehicle for coated drug particles | |
| JP2003306428A (ja) | 服用性を改善した硬カプセル剤 | |
| JP3343144B2 (ja) | マイクロカプセル | |
| CN100482227C (zh) | 一种复方缓释胶囊及其制备方法 | |
| Fulzele et al. | Drug Delivery: Fast Dissolve Systems | |
| AU2005299253A1 (en) | Improved tabletting process |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080514 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20080514 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110726 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20111025 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20111101 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20111108 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20111115 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120125 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120925 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20121115 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20121217 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20130109 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 5178982 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| LAPS | Cancellation because of no payment of annual fees |